Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

New discovery enhances feasibility of cardiovascular gene therapy

Oct. 8, 1997

FDA approves irbesartan for marketing

Oct. 8, 1997

Millennium and Lilly extend cardiovascular research collaboration

Oct. 7, 1997

HMR and Andrx agree to stipulation in Cardizem CD patent lawsuit

Oct. 7, 1997

Cytokine synthesis inhibitor protects against polymicrobial sepsis in animal model

Oct. 6, 1997

Novel class III antiarrhythmic agents described by Merck & Co.

Oct. 6, 1997

Cypros to start phase III trial for CABG

Oct. 3, 1997

Focus on benzoyl guanidines as Na+/H+-exchange inhibitors

Oct. 2, 1997

Cytel reports encouraging results from Cylexin phase I/II trial

Oct. 2, 1997

Single- and multiple-dose clinical studies reported for SL-91.0102

Oct. 1, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...